Tucatinib combined with radiation for HER2-positive breast cancer with leptomeningeal disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and efficacy of combining radiation therapy with systemic treatment using Tucatinib, Trastuzumab, and Capecitabine in patients with HER2-positive metastatic breast cancer who also have leptomeningeal disease. The approach aims to improve survival outcomes for patients who typically face a poor prognosis due to central nervous system involvement. The study will assess the impact of this combination therapy on overall survival and quality of life. Participants will undergo radiation therapy followed by the systemic treatment regimen.

Why it matters

Who can join: the full rules

Inclusion Criteria: Phase 1

1. Men or women with HER2+, HER2 mutated and/or HER2-amplified metastatic breast cancer. HER2+ status will be defined in accordance with ASCO-CAP 2018 guidelines, and can be diagnosed at any time prior to enrolment. HER2 mutations and/or HER2-amplifications can be identified in the blood and/or cerebrospinal fluid (CSF) at any time prior to enrolment; testing blood and/or CSF is not part of the study protocol and must be evaluated using a clinically validated test.
2. Evidence of LMD\* in the brain and/or spine (either positive cerebral spinal fluid cytology and/or magnetic resonance imaging evidence of LMD). Measurable disease in the central nervous system is not required. \* The diagnosis of LMD can occur at any time prior to enrolment;
3. Age 18+ at time of consent;
4. ECOG ≤ 2;
5. More than 14 days or 5 half-lives from the last dose of any experimental agent is required, whichever is greater;
6. All toxicity related to prior cancer therapies must have resolved to ≤ Grade 1 prior to enrollment, except for alopecia; neuropathy, must have resolved to ≤ Grade 2.

Phase 2: Inclusion Criteria

1. Left ventricular ejection fraction (LVEF) must be within institutional limits of normal as assessed by ECHO or MUGA documented within 2 weeks prior to starting systemic therapy on the study;
2. Adequate hematologic, liver, and renal function within 2 weeks prior to phase 2 enrollment, as follows:

   1. Hemoglobin ≥ 9 g/dL
   2. ANC ≥ 1 x109/L
   3. Platelets ≥ 100 x109/L
   4. Total bilirubin ≤ 1.5 X upper limit of normal (ULN)
   5. AST and ALT ≤ 2.5X ULN
   6. International normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5 X ULN
   7. Creatinine clearance (CrCL) ≥ 50 mL/min
3. The last dose of prior therapy must have been completed 14 days prior to study enrollment. Prior chemotherapy, immunotherapy, endocrine therapy, targeted therapy and experimental agents are allowed (including prior use of trastuzumab or other antibody-based therapy). Prior use of capecitabine either alone or in combination with other HER2-targeted therapies (including other tyrosine kinase inhibitors) is permitted;

Exclusion Criteria: Phase 1

1. Prior WBRT for brain metastases (prior stereotactic radiosurgery for parenchymal CNS metastases received \<7 days prior to consent );
2. Prior therapy specifically directed at LMD, including prior radiotherapy or systemic therapy;
3. Inability to comply with MRI-based surveillance of CNS disease;
4. Inability to swallow pills or any significant gastrointestinal diseases such as inflammatory bowel disease who suffer from uncontrolled diarrhea (based on the investigator's assessment),, which would preclude adequate absorption of oral medications;
5. Diagnosed with Hereditary fructose intolerance;
6. Diagnosed with Gilbert's disease;
7. Prior history of other cancer (except non melanoma skin, cervical intraepithelial neoplasia) with evidence of disease within the last 5 years;
8. Prior use of tucatinib at any time prior to enrollment.
9. Hypersensitivity to any of the active substances in tucatinib, trastuzumab, or capecitabine.

Phase 2:

1. Currently pregnant or breastfeeding;
2. Use of a strong cytochrome P450 (CYP)2C8 inhibitor within 5 half-lives of the inhibitor or use of a strong CYP3A4 or CYP2C8 inducer within 5 days prior to the first dose of systemic therapy (see Appendix C and D);
3. Myocardial infarction or unstable angina within 6 months prior to the first dose of systemic therapy.
4. Blood product transfusions in order to meet eligibility criteria

Where it's running

• The Ottawa Hospital
  Ottawa, Ontario, Canada Recruiting
• Sunnybrook Health Sciences Centre
  Toronto, Ontario, Canada Recruiting

Study contacts

• Study coordinator: CLIMB-LMD Project Manager
• Email: CLIMB-LMD@sunnybrook.ca
• Phone: 437-247-2617

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• RO7771950 versus tucatinib with trastuzumab and capecitabine for HER2-positive locally advanced or metastatic breast cancer

  This test will see if RO7771950 combined with trastuzumab and capecitabine works better than tucatinib combined with the same drugs for people with HER2-positive locally advanced or metastatic breast cancer.

  Recruiting at 219 sites Phase 2/3 Hoffmann-La Roche · Huntsville, Alabama and 218 other locations · NCT07413939

• Combination treatment for metastatic HER2-positive breast cancer

  This study is testing a new combination of medications for people with HER2-positive metastatic breast cancer who haven't responded to previous treatments, to see if it can help them feel better and manage their disease.

  Recruiting at 9 sites Phase 2 Institut Curie · Clermont-Ferrand, Clermont Ferrand and 12 other locations · NCT05955170

• Entinostat with Pyrotinib and Endocrine Therapy in HER2-positive, HR-positive Advanced Breast Cancer after Trastuzumab Failure

  This study tests whether adding entinostat to pyrotinib and hormone therapy is safe and helps patients with advanced HR+/HER2+ breast cancer who progressed after trastuzumab.

  Recruiting Phase 1/2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07708194

• GQ1005 versus T-DM1 in HER2-positive unresectable or metastatic breast cancer

  This trial tests whether GQ1005 works as well as T-DM1 for adults with HER2-positive unresectable or metastatic breast cancer who have already had trastuzumab and taxane.

  Recruiting at 70 sites Phase 3 GeneQuantum Healthcare (Suzhou) Co., Ltd. · Bengbu, Anhui and 69 other locations · NCT07673029

• Trastuzumab Rezetecan Neoadjuvant Therapy for HER2-Positive Breast Cancer

  This trial tests whether adding trastuzumab rezetecan after an initial THP treatment helps patients with HER2-positive breast cancer decide if they should switch therapies based on response.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07647263

• Pyrotinib plus trastuzumab and chemotherapy for HER2-positive early breast cancer

  This study tests a treatment combination of Pyrotinib, Trastuzumab and chemo given before surgery to see if it can improve responses in HER2-positive breast cancer patients who have not yet been treated.

  Recruiting Phase 2 Hebei Medical University Fourth Hospital · Shijiazhuang, Hebei · NCT07635342

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.